Over the past few decades, si
RNA
and mi
RNA
have attracted a great deal of attention from researchers and clinicians. These molecules have been extensively studied from the standpoint of developing biopharmaceuticals against various diseases, including heart disease, diabetes and cancers. si
RNA
suppresses only a single target, whereas each mi
RNA
regulates the expression of multiple target genes. More importantly, because mi
RNA
are also secreted from cancer cells, and their aberrant expression is associated with tumor development and progression, they represent not only therapeutic targets but also promising biomarkers for diagnosis and prognosis. Therefore, mi
RNA
may be more effective tools against cancers, in which multiple signal pathways are dysregulated. In this review, we summarize recent progress in the development of mi
RNA
therapeutics for the treatment of cancer patients, and describe delivery systems for oligonucleotide therapeutics.